id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9359 R32739 |
Tomson (Valproate), 2018 | Polydactyly | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 31.13 [1.80;539.82] C | 8/1,381 0/2,514 | 8 | 1,381 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9309 R32430 |
Källén (Valproate) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013 | Poly/syndactyly | early pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.52 [0.05;4.99] C excluded (control group) |
1/697 3/1,084 | 4 | 697 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9310 R32438 |
Källén (Valproate) (Controls unexposed, NOS) (Indications NOS), 2013 | Poly/syndactyly | early pregnancy | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: No | 0.73 [0.10;5.21] C | 1/697 3,084/1,575,847 | 3,085 | 697 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9331 R32554 |
Bànhidy (Valproate), 2011 | Poly/syndactyly | throughout pregnancy | case control | unexposed, sick | Adjustment: No Matched | 0.58 [0.02;16.72] C | 0/5 2/12 | 2 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9329 R32531 |
Viinikainen (Valproate) (Controls unexposed, sick) a, 2006 | Polydactyly | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 1.87 [0.04;96.99] C | 0/28 0/52 | 0 | 28 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9297 R32300 |
D'Souza (Valproate) (Controls unexposed, disease free), 1991 | Extra digits | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
123.00 [1.00;15058.31] C excluded (control group) |
0/1 0/62 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9298 R32329 |
D'Souza (Valproate) (Controls unexposed, sick), 1991 | Extra digits | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 15.00 [0.12;1923.88] C | 0/1 0/8 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 2.55 [0.48;13.67] | 3,095 | 2,112 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate; 2: Valproate) (Controls unexposed, NOS) (Indications NOS; 3: Valproate; 4: Valproate) (Controls unexposed, sick) ; 5: Valproate) (Controls unexposed, sick;
Asymetry test p-value = 0.4933 (by Egger's regression)
slope=-1.2575 (2.7477); intercept=1.4239 (1.8302); t=0.7780; p=0.4933
excluded 9297, 9309